First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

  1. Albiges, L.
  2. Tannir, N.M.
  3. Burotto, M.
  4. McDermott, D.
  5. Plimack, E.R.
  6. Barthélémy, P.
  7. Porta, C.
  8. Powles, T.
  9. Donskov, F.
  10. George, S.
  11. Kollmannsberger, C.K.
  12. Gurney, H.
  13. Grimm, M.-O.
  14. Tomita, Y.
  15. Castellano, D.
  16. Rini, B.I.
  17. Choueiri, T.K.
  18. Leung, D.
  19. Saggi, S.S.
  20. Lee, C.-W.
  21. McHenry, M.B.
  22. Motzer, R.J.
Aldizkaria:
European Urology

ISSN: 1873-7560,  0302-2838

Argitalpen urtea: 2022

Alea: 81

Zenbakia: 3

Orrialdeak: 266-271

Mota: Artikulua

DOI: 10.1016/J.EURURO.2021.10.001 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus